Heartstream Launched as Independent Emergency Care Company
Heartstream Launched as Independent Emergency Care Company
Amplifire Transforms Epic Training: New KLAS Case Study Shows 75% Reduction in Training Time
Amplifire Transforms Epic Training: New KLAS Case Study Shows 75% Reduction in Training Time
New report reveals 2026 benefits trends: More HDHPs, preventive care, and AI-powered savings
New Eden member perks include free access to AI-powered workout plans through Aaptiv—no purchase or credit card required. DENVER, June 4,...
Leading oncology research organization adopts Veeva Clinical Platform to enhance study delivery PLEASANTON, Calif. and NASHVILLE, Tenn., June 4, 2025...
Vault CRM will support Astellas' commercial agility and execution PLEASANTON, Calif., June 4, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today...
- Further protection granted in key territory applying to the significant and growing aesthetic and reconstructive markets - REHOVOT, Israel,...
STRATFORD, Conn., June 4, 2025 /PRNewswire/ -- This week marks a major milestone for KUBTEC®, as the company celebrates its...
Merger brings together clinical care, technology, logistics, and scale to simplify how serious health needs are treated where people are...
A large heart imaging study previously undertaken at Queen Mary University of London (QMUL) and Barts Health NHS Trust tested...
Oncovita receives FDA Orphan Drug Designation for its lead oncolytic virus candidate MVdeltaC in the treatment of pleural mesothelioma Paris,...
Aortic Stenosis is a Serious and Widespread Condition; The AI-ECG Algorithm Offers a Powerful Diagnostic Solution Designed for Seamless Integration...
Annamycin delivering better performance 7th line than would be expected even in 2nd line for monotherapy Responders (Stable Disease or...
Glucotrack to present on next-generation continuous blood glucose monitoring technology in Innovation Hub Poster presentation to highlight insights on safety...
Supports late-stage development and scalable manufacturing for LP-310, a non-steroidal oral rinse therapy for Oral Lichen Planus, a condition with...
LOS ANGELES, June 04, 2025 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Expert Market: VDRM), a specialty pharmaceutical company, today announced...
Collaboration leverages cutting-edge reformulation expertise to generate cross-species insights, fast-track human clinical programs, and seeks to capture commercial potential in...
WEST PALM BEACH, FLORIDA, June 04, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”) today...
Designation Supported by CLOVER WaM Phase 2 Study DataWhich Reported an 83.6% Overall Response Rate (ORR) Seeking Guidance from EMA...
Phase 11 First-In-Human study designed to assess safety, tolerability, right dose for Phase 2 and early signs of efficacy of...
Funding expected to support operations into Q1 2026. Anticipated AMPLIFY-7P Phase 2 interim analysis expected in Q3 2025. BOSTON, June...
Underscores Hydrafacial’s leadership and value to providers and consumers Hydrafacial Syndeo Device An esthetician uses a Hydrafacial Syndeo device to...
Akebia continues to publish important, clinically relevant data to further physicians’ understanding of Vafseo® (vadadustat)CAMBRIDGE, Mass., June 04, 2025 (GLOBE...
